ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 2574 • ACR Convergence 2023

    Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract

    Gabriela Martinez Zayas1, David Karp1 and Elena Joerns2, 1UT Southwestern Medical Center, Dallas, TX, 2University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society and American Thoracic Society Task Force for those…
  • Abstract Number: 0289 • ACR Convergence 2023

    Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity

    Sangmee Bae1, Ani Shahbazian1, Jennifer Wang2, Tiffany De Leon1, Yuna Lee1, srinivasa Reddy3 and Christina Charles-Schoeman4, 1UCLA Rheumatology, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, 4UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Damage to the vascular endothelium is implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM) and its associated interstitial lung disease (ILD), with microvascular…
  • Abstract Number: 0643 • ACR Convergence 2023

    Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression

    Anna-Maria Hoffmann-Vold1, Liubov Petelytska2, Havard Fretheim1, Trond Mogens Aaløkken3, Mike Becker4, Hilde Jenssen Bjørkekjær5, Cathrine Brunborg6, Cosimo Bruni7, Christian Clarenbach8, Phuong Phuong Diep9, Rucsandra Dobrota7, Michael Durheim10, Muriel Elhai11, Thomas Frauenfelder12, Suzana Jordan7, Emily Langballe13, Oyvind Midtvedt1, Carina Mihai7, Oyvind Molberg14 and Oliver Distler7, 1Oslo University Hospital, Oslo, Norway, 2Bogomolets National Medical University, Kyiv, Ukraine, 3Dept of Radiology, Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 6Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 9Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, 10Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, 11University Hospital zurich, University of Zurich, Zurich, Switzerland, 12Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 13Universitetet i Oslo, Oslo, Norway, 14Dept of Rheumatology, University Hospital Oslo, Oslo, Norway

    Background/Purpose: In clinical practice, we often wait for progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) to initiate or escalate therapy. Similarly, progressive…
  • Abstract Number: 0808 • ACR Convergence 2023

    Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System

    Bryant England1, Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Daniel Hershberger1, Brian Sauer2, Grant Cannon3, Joshua Baker4 and Ted R Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4University of Pennsylvania, Philadelphia, PA, 5Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…
  • Abstract Number: 1240 • ACR Convergence 2023

    Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash

    Ilaria Maccora1, Patricia Vega-Fernandez2, Kimberly Risma3 and Grant Schulert4, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2Division of Rheumatology, Cincinnati Children's Hospital, Medical Centre, Cincinnati, OH, 3Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…
  • Abstract Number: 1704 • ACR Convergence 2023

    Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma

    gerlando Natalello1, enrico De Lorenzis1, Ludovica Berardini2, lucrezia verardi1, pier giacomo Cerasuolo1, Alfredo Papa3, Italo De Vitis3, Francesco Varone2, Luca Richeldi2, Maria Antonietta D'Agostino1 and Silvia Bosello1, 1Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 2Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 3Division of Gastroenterology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…
  • Abstract Number: 2140 • ACR Convergence 2023

    Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis

    Ted R Mikuls1, Bryant England2, Harlan Sayles2, Tate Johnson2, Michael Duryee2, Carlos Hunter2, Joshua Baker3, Gail Kerr4, Gary Kunkel5, Grant Cannon6, Brian Sauer7, K Wysham8, Amy Joseph9, Beth Wallace10, Geoffrey Thiele2 and Jill Poole2, 1Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Pennsylvania, Philadelphia, PA, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT, 7Salt Lake City VA/University of Utah, Salt Lake City, UT, 8VA Puget Sound/University of Washington, Seattle, WA, 9Washington University / St. Louis VA, St. Louis, MO, 10Ann Arbor VA, Ann Arbor, MI

    Background/Purpose: Alarmins are proteins found in the nuclei of epithelial, endothelial, and immune cells that are released following cell damage and act as stress signals.…
  • Abstract Number: 2594 • ACR Convergence 2023

    Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

    Oliver Distler1, Madelon Vonk2, Arata Azuma3, Maureen Mayes4, Dinesh Khanna5, Kristin B Highland6, Gerrit Toenges7, Margarida Alves8 and Yannick Allanore9, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan, and Meisei Hospital, Saitama, Japan, 4Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 5University of Michigan, Ann Arbor, MI, 6Cleveland Clinic, Cleveland, OH, 7Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 9Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France

    Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…
  • Abstract Number: 0293 • ACR Convergence 2023

    Characteristics and Outcomes of Idiopathic Inflammatory Myositis Associated Interstitial Lung Disease in Rural Appalachia

    FNU Rida Ul Jannat, Sayanika Kaur, Bathmapriya Balakrishnan, Vishal Deepak, Bhanusowmya Buragamadagu, Rachel Salyer and Ty Landis, West Virginia University Hospital, Morgantown, WV

    Background/Purpose: Interstitial lung disease (ILD) can affect up to 30% of the patients with idiopathic inflammatory myositis (IIM) and contributes significantly towards morbidity and mortality…
  • Abstract Number: 0644 • ACR Convergence 2023

    Prediction of Stable SSc-ILD Depends on Definition of ILD Progression

    Anna-Maria Hoffmann-Vold1, Liubov Petelytska2, Havard Fretheim1, Trond Mogens Aaløkken3, Mike Becker4, Cathrine Brunborg5, Cosimo Bruni6, Christian Clarenbach7, Phuong Phuong Diep8, Rucsandra Dobrota6, Michael Durheim9, Muriel Elhai10, Thomas Frauenfelder11, Suzana Jordan6, Emily Langballe12, Carina Mihai6, Oyvind Midtvedt1, Oyvind Molberg13 and Oliver Distler6, 1Oslo University Hospital, Oslo, Norway, 2Bogomolets National Medical University, Kyiv, Ukraine, 3Dept of Radiology, Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 6Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, 9Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, 10University Hospital zurich, University of Zurich, Zurich, Switzerland, 11Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 12Universitetet i Oslo, Oslo, Norway, 13Dept of Rheumatology, University Hospital Oslo, Oslo, Norway

    Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
  • Abstract Number: 0939 • ACR Convergence 2023

    HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease

    David Lauer1, Luca Romano Kolly1, Hubert Gabrys2, Matthias Brunner1, Malgorzata Anna Maciukiewicz1, Thomas Frauenfelder3, Stephanie Tanadini-Lang2, Anne-Christine Uldry4, Manfred Heller4, Kerstin Klein5, Oliver Distler6, Janine Gote-Schniering1 and Britta Maurer7, 1University Hospital Bern, Bern, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 4University of Bern, Bern, Switzerland, 5Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland, 6Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7University Hospital Bern, University Bern, Bern, Switzerland

    Background/Purpose: Quantification of response to anti-fibrotic drugs in patients with fibrosing interstitial lung disease (ILD) relies on repeated pulmonary function tests (PFT) and visual evaluation…
  • Abstract Number: 1269 • ACR Convergence 2023

    The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes

    Gregory McDermott1, Keigo Hayashi1, Pierre-Antoine Juge2, Ritu Gill1, Suzanne Byrne1, Staci Gagne1, Kathleen Vanni1, Emily Kowalski1, Grace Qian1, Katarina Bade3, Alene Saavedra1, Yumeko Kawano1, Michael Diiorio3, Taylor Wolfgang1, Edy Kim1, Paul Dellaripa3, Michael Weinblatt4, Nancy Shadick3, Tracy J. Doyle1 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Harvard Medical School, Waban, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
  • Abstract Number: 1724 • ACR Convergence 2023

    Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects

    Hanna Lee1, Suhee Kim2, Mingyo Kim2, Ok-Yi Jeong3 and Sang-Il Lee2, 1Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, South Korea, 2Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Hospital, JinJu, South Korea, 3Division of Rheumatology, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea

    Background/Purpose: Interstitial lung disease (ILD) is a serious condition characterized by inflammation and fibrosis in the lung interstitium. The important subtypes of ILD include idiopathic…
  • Abstract Number: 2158 • ACR Convergence 2023

    Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON

    Eric Matteson1, Danielle Antin-Ozerkis2, Francesco Bonella3, Nazia Chaudhuri4, Vincent Cottin5, Heiko Mueller6, Steven Sambevski7 and Wim A Wuyts8, 1Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, 2Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, 3Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 4North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, 5Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 8Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium

    Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…
  • Abstract Number: 2595 • ACR Convergence 2023

    A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)

    Shefali Khanna Sharma1, Jithin Mathew1, Chirag Kopp1, Varun Dhir2, Sahajal Dhooria3, Anindita Sinha1 and Sanjay Jain1, 1Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER, CHD, INDIA, Chandigarh, India, 3PGI CHANDIGARH, Chandigarh, India

    Background/Purpose: Interstitial lung disease in systemic sclerosis(SSc-ILD) is heterogeneous with limited therapeutic options. Mycophenolate mofetil (MMF) is the most commonly used first line agent for…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 39
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology